<p>Aromatase is an enzyme that facilitates the conversion of androgens to estrogens and may play a role in mood and mental status. The main theme of this thesis is the imaging of brain aromatase by use of the PET technique. The PET tracer for aromatase, ¹¹C-labeled vorozole (VOZ) was developed and evaluated by with <i>in vitro</i> and <i>in vivo</i> methods. <i>In vitro</i> experiments using rat brain showed that VOZ was distributed in the medial amygdala, bed nucleus of the stria terminalis and medial preoptic area, regions of the brain known to be rich in aromatase and the K_D value was determined to be 0.60 nM. The <i>in vivo</i> PET study in rhesus monkey brain revealed that VOZ penetrated the blood-brain barrier and accumulated in the amygdala and hypothalamus. Taken together, VOZ is a good PET tracer for <i>in vivo</i> aromatase imaging with high affinity and high sensitivity.</p><p>This technique was applied to an investigation of brain aromatase under the physiological conditions simulating anabolic-androgenic steroid abuse. A significant increase in VOZ binding by anabolic-androgenic steroids was observed in the bed nucleus of stria terminalis and medial preoptic area in the rat brain. In contrast, no significant change in binding was observed in the medial amygdala. These results indicate that the manner of regulation of aromatase expression might be different in the bed nucleus of stria terminalis and medial preoptic area compared with that in the medial amygdala. The aromatase expression was suggested to be regulated through androgen receptors, as indicated in a study with flutamide treatment. The increased aromatase expression was seen in neurons. The PET study with anabolic steroid-treated rhesus monkeys also showed increased VOZ binding in the hypothalamus but not in the amygdala. The alteration of density of aromatase binding in the hypothalamic area could explain some psychological features of anabolic-androgenic steroid abusers.</p><p>Novel PET tracers for aromatase were developed and examined. The two newly synthesized ¹⁸F-labeled vorozole analogs, [¹⁸F]FVOZ and [¹⁸F]FVOO, displayed different characteristics. Both tracers showed similar binding pattern as VOZ; however, [¹⁸F]FVOO was metabolized very quickly, meaning that this tracer is not suitable as a PET tracer. On the other hand, [¹⁸F]FVOZ can be an appropriate PET tracer.</p><p>The role of aromatase in the human brain has not been clarified yet. To approach this problem by<i> in vivo</i> methods, we have just started PET studies to explore aromatase expression in humans.</p>

Un déséquilibre de la balance énergétique constitue la principale cause du développement des pathologies métaboliques telles que l’obésité et le diabète de type 2. Au sein du cerveau, l’hypothalamus joue un rôle primordial dans le contrôle de la prise alimentaire et du métabolisme périphérique via le système nerveux autonome. Ce contrôle, repose sur l’existence de différentes populations neuronales au sein de l’hypothalamus médio-basal (MBH), neurones à neuropeptide Y (NPY)/Agouti-related peptide (AgRP), et neurones a proopiomelanocortine (POMC), dont l’activité est directement modulée par les variations des taux circulants des nutriments tels que le glucose et les acides gras (FA). Alors que les mécanismes de détection et le métabolisme intracellulaire du glucose ont été largement étudiés, l’implication du métabolisme intracellulaire des FA dans leurs effets centraux, est très peu comprise. De plus, on ignore si le glucose, module le métabolisme intracellulaire des acides gras à longue chaine (LCFA) dans le MBH. Le but de notre première étude est, de déterminer l'impact du glucose sur le métabolisme des LCFA, le rôle de l’AMP-activated protein kinase (AMPK), kinase détectrice du statut énergétique cellulaire, et d'établir s’il y a des changements dans le métabolisme des LCFA en fonction de leur structure, du type cellulaire et de la région cérébrale. Nos résultats montrent que le glucose inhibe l'oxydation du palmitate via l’AMPK dans les neurones et les astrocytes primaires hypothalamiques, in vitro, ainsi que dans les explants du MBH, ex vivo, mais pas dans les astrocytes et les explants corticaux. De plus, le glucose augmente l'estérification du palmitate et non de l’oléate dans les neurones et les explants du MBH, mais pas dans les astrocytes hypothalamiques. Ces résultats décrivent le devenir métabolique de différents LCFA dans le MBH, ainsi que, la régulation AMPK - dépendante de leur métabolisme par le glucose dans les astrocytes et les neurones, et démontrent pour la première fois que le métabolisme du glucose et des LCFA est couplé spécifiquement dans les noyaux du MBH, dont le rôle est critique pour le contrôle de l'équilibre énergétique. Le deuxième volet de cette thèse s’est intéressé à déterminer les mécanismes intracellulaires impliqués dans le rôle de la protéine de liaison ACBP dans le métabolisme central des FA. Nous avons démontré que le métabolisme de l’oléate et non celui du palmitate est dépendant de la protéine ACBP, dans les astrocytes hypothalamiques ainsi que dans les explants du MBH. Ainsi, nos résultats démontrent qu’ACBP, protéine identifiée originellement au niveau central, comme un modulateur allostérique des récepteurs GABA, agit comme un régulateur du métabolisme intracellulaire des FA. Ces résultats ouvrent de nouvelles pistes de recherche liées à la régulation du métabolisme des acides gras au niveau central, ainsi que, la nouvelle fonction de la protéine ACBP dans la régulation du métabolisme des FA au niveau du système nerveux central. Ceci aiderait à identifier des cibles moléculaires pouvant contribuer au développement de nouvelles approches thérapeutiques de pathologies telles que l’obésité et le diabète de type 2. / An imbalance of energy balance is the main cause of the development of metabolic diseases such as obesity and type 2 diabetes. Within the brain, the hypothalamus plays an important role in the control of food intake and peripheral metabolism, via the autonomic nervous system. This control relies on the existence of different neuronal populations in the medio-basal hypothalamus (MBH), including neuropeptide Y (NPY), agouti-related peptide (AgRP) and proopiomelanocortin (POMC) neurons, the activity of which, is directly modulated by changes in the circulating levels of nutrients such as glucose and fatty acids (FA). While mechanisms governing the detection and the intracellular metabolism of glucose have been extensively studied, the involvement of FA intracellular metabolism, in their central effects is poorly understood. It is currently unknown if glucose regulates long chain fatty acids (LCFA) metabolism in the MBH. The aim of our first study was to determine the impact of glucose on LCFA metabolism, assess the role of AMP-activated Kinase (AMPK), a sensor of cellular energy status, and to establish if changes in LCFA metabolism, and its regulation by glucose, vary as a function of LCFA type, cell type and brain region. We show that glucose inhibits palmitate oxidation via AMPK in hypothalamic neuronal cell lines, primary hypothalamic astrocyte cultures and MBH slices, ex vivo, but not in cortical astrocytes and slice preparations. In addition, our results show that glucose increases palmitate but not oleate esterification into neutral lipids, in neurons and MBH slices, but not in hypothalamic astrocytes. These findings reveal the metabolic fate of different LCFA in the MBH, demonstrate AMPK-dependent glucose regulation of LCFA oxidation in both astrocytes and neurons and established for the first time the metabolic coupling of glucose and LCFA as a specific feature of the MBH, whose role is critical for the control of energy balance. During the second part of this thesis, we were interested to determine the intracellular mechanisms involved in the role of Acyl-CoA binding protein (ACBP), in the central metabolism of FA. We have shown that the metabolism of oleate but not palmitate is ACBP -dependent in hypothalamic astrocytes and MBH slices. Thus, our results demonstrate That ACBP, a protein originally identified as an allosteric modulator of GABA receptor peptide, acts as a regulator of intracellular metabolism of FA. These results open a new avenues of research related to the central regulation of fatty acid metabolism and the new function of ACBP protein in the regulation of FA metabolism in the central nervous system, which could help to identify molecular targets that may contribute to the development of new therapeutic approaches of diseases such as obesity and type 2 diabetes.

L’obésité provient d’un déséquilibre de l’homéostasie énergétique, c’est-à-dire une augmentation des apports caloriques et/ou une diminution des dépenses énergétiques. Plusieurs données, autant anatomiques que physiologiques, démontrent que l’hypothalamus est un régulateur critique de l’appétit et des dépenses énergétiques. En particulier, le noyau paraventriculaire (noyau PV) de l’hypothalamus intègre plusieurs signaux provenant du système nerveux central (SNC) et/ou de la périphérie, afin de contrôler l’homéostasie énergétique via des projections axonales sur les neurones pré-ganglionnaires du système autonome situé dans le troc cérébral et la moelle épinière. Plusieurs facteurs de transcription, impliqués dans le développement du noyau PV, ont été identifiés. Le facteur de transcription SIM1, qui est produit par virtuellement tous les neurones du noyau PV, est requis pour le développement du noyau PV. En effet, lors d’une étude antérieure, nous avons montré que le noyau PV ne se développe pas chez les souris homozygotes pour un allèle nul de Sim1. Ces souris meurent à la naissance, probablement à cause des anomalies du noyau PV. Par contre, les souris hétérozygotes survivent, mais développent une obésité précoce. De façon intéressante, le noyau PV des souris Sim1+/- est hypodéveloppé, contenant 24% moins de cellules. Ces données suggèrent fortement que ces anomalies du développement pourraient perturber le fonctionnement du noyau PV et contribuer au développement du phénotype d’obésité. Dans ce contexte, nous avons entrepris des travaux expérimentaux ayant pour but d’étudier l’impact de l’haploinsuffisance de Sim1 sur : 1) le développement du noyau PV et de ses projections neuronales efférentes; 2) l’homéostasie énergétique; et 3) les voies neuronales physiologiques contrôlant l’homéostasie énergétique chez les souris Sim1+/-. A cette fin, nous avons utilisé : 1) des injections stéréotaxiques combinées à des techniques d’immunohistochimie afin de déterminer l’impact de l’haploinsuffisance de Sim1 sur le développement du noyau PV et de ses projections neuronales efférentes; 2) le paradigme des apports caloriques pairés, afin de déterminer l’impact de l’haploinsuffisance de Sim1 sur l’homéostasie énergétique; et 3) une approche pharmacologique, c’est-à-dire l’administration intra- cérébroventriculaire (i.c.v.) et/ou intra-péritonéale (i.p.) de peptides anorexigènes, la mélanotane II (MTII), la leptine et la cholécystokinine (CCK), afin de déterminer l’impact de l’haploinsuffisance de Sim1 sur les voies neuronales contrôlant l’homéostasie énergétique. Dans un premier temps, nous avons constaté une diminution de 61% et de 65% de l’expression de l’ARN messager (ARNm) de l’ocytocine (Ot) et de l’arginine-vasopressine (Vp), respectivement, chez les embryons Sim1+/- de 18.5 jours (E18.5). De plus, le nombre de cellules produisant l’OT et la VP est apparu diminué de 84% et 41%, respectivement, chez les souris Sim1+/- adultes. L’analyse du marquage axonal rétrograde des efférences du noyau PV vers le tronc cérébral, en particulier ses projections sur le noyau tractus solitaire (NTS) aussi que le noyau dorsal moteur du nerf vague (X) (DMV), a permis de démontrer une diminution de 74% de ces efférences. Cependant, la composition moléculaire de ces projections neuronales reste inconnue. Nos résultats indiquent que l’haploinsuffisance de Sim1 : i) perturbe spécifiquement le développement des cellules produisant l’OT et la VP; et ii) abolit le développement d’une portion importante des projections du noyau PV sur le tronc cérébral, et notamment ses projections sur le NTS et le DMV. Ces observations soulèvent donc la possibilité que ces anomalies du développement du noyau PV contribuent au phénotype d’hyperphagie des souris Sim1+/-. En second lieu, nous avons observé que la croissance pondérale des souris Sim1+/- et des souris Sim1+/+ n’était pas significativement différente lorsque la quantité de calories présentée aux souris Sim1+/- était la même que celle consommée par les souris Sim1+/+. De plus, l’analyse qualitative et quantitative des tissus adipeux blancs et des tissus adipeux bruns n’a démontré aucune différence significative en ce qui a trait à la taille et à la masse de ces tissus chez les deux groupes. Finalement, au terme de ces expériences, les souris Sim1+/--pairées n’étaient pas différentes des souris Sim1+/+ en ce qui a trait à leur insulinémie et leur contenu en triglycérides du foie et des masses adipeuses, alors que tous ces paramètres étaient augmentés chez les souris Sim1+/- nourries ad libitum. Ces résultats laissent croire que l’hyperphagie, et non une diminution des dépenses énergétiques, est la cause principale de l’obésité des souris Sim1+/-. Par conséquent, ces résultats suggèrent que : i) l’haploinsuffisance de Sim1 est associée à une augmentation de l’apport calorique sans toutefois moduler les dépenses énergétiques; ii) l’existence d’au moins deux voies neuronales issues du noyau PV : l’une qui régule la prise alimentaire et l’autre la thermogénèse; et iii) l’haploinsuffisance de Sim1 affecte spécifiquement la voie neuronale qui régule la prise alimentaire. En dernier lieu, nous avons montré que l’injection de MTII, de leptine ainsi que de CCK induit une diminution significative de la consommation calorique des souris des deux génotypes, Sim1+/+ et Sim1+/-. De fait, la consommation calorique cumulative des souris Sim1+/- et Sim1+/+ est diminuée de 37% et de 51%, respectivement, durant les 4 heures suivant l’administration i.p. de MTII comparativement à l’administration d’une solution saline. Lors de l’administration i.c.v. de la leptine, la consommation calorique cumulative des souris Sim1+/- et Sim1+/+ est diminuée de 47% et de 32%, respectivement. Finalement, l’injection i.p. de CCK diminue la consommation calorique des souris Sim1+/- et Sim1+/+ de 52% et de 36%, respectivement. L’ensemble des résultats suggère ici que l’haploinsuffisance de Sim1 diminue l’activité de certaines voies neuronales régulant l’homéostasie énergétique, et particulièrement de celles qui contrôlent la prise alimentaire. En résumé, ces travaux ont montré que l’haploinsuffisance de Sim1 affecte plusieurs processus du développement au sein du noyau PV. Ces anomalies du développement peuvent conduire à des dysfonctions de certains processus physiologiques distincts régulés par le noyau PV, et notamment de la prise alimentaire, et contribuer ainsi au phénotype d’obésité. Les souris hétérozygotes pour le gène Sim1 représentent donc un modèle animal unique, où l’hyperphagie, et non les dépenses énergétiques, est la principale cause de l’obésité. En conséquence, ces souris pourraient représenter un modèle expérimental intéressant pour l’étude des mécanismes cellulaires et moléculaires en contrôle de la prise alimentaire. / Obesity arises from imbalance of the energy homeostasis processes. Multiple anatomical and physiological evidence demonstrate the involvement of the hypothalamus in the regulation of energy homeostasis, i.e. appetite and energy expenditure. In particular, the paraventricular nucleus (PVN) of the hypothalamus plays a critical role in these important homeostatic processes. The PVN integrates multiple signals that come from the central nervous system and/or the periphery to control energy homeostasis. It regulates these processes through projections to the dorsal vagal complex (DVC), which includes the dorsal motor nucleus of the vagus (X) (DMV) and the adjacent nucleus of the solitary tract (NST), located in the brainstem. A cascade of transcription factors involved in the specification of the PVN neurons has been described. One component of this cascade, the bHLH-PAS transcription factor SIM1, is required for the development of all neurons of the PVN. Mice homozygous for null alleles of Sim1 die shortly after birth, presumably because of the lack of PVN. In contrast, Sim1 heterozygous mice survive but show early-onset obesity. Interestingly, the number of PVN cells is reduced by 24% in Sim1+/- mice, suggesting that developmental defects may cause PVN dysfunction and, thus, contribute to the obesity phenotype. In order to explore this hypothesis, we studied the impact of Sim1 haploinsufficiency on: 1) the development of the PVN and it efferent axonal projections; 2) energy homeostasis; and 3) neuronal pathways regulating energy homeostasis. We used: 1) stereotaxic injections and immunological techniques to determine the impact of Sim1 haploinsufficiency on PVN, and it efferent axonal projections, development; 2) the pair-feeding paradigm to determine the impact of Sim1 haploinsufficiency on energy homeostasis; and 3) intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) injections of pharmacological agents, melanotan II (MTII), leptin and cholecystokinin (CCK), to determine the impact of Sim1 haploinsufficiency on the neuronal pathways regulating energy homeostasis. First, we noted that the expression of oxytocin (Ot) and argenin-vasopressin (Vp) mRNA is reduced by 61% and 65%, respectively, in the PVN of Sim1+/- E18.5 embryos. Furthermore, the number of OT- and VP-producing cells was found to be decreased by 84% and 41%, respectively, in Sim1+/- adult mice. Analysis of the retrograde axonal labelling of PVN neurons after stereotaxic injection of latex beads into the DVC of Sim1+/+ and Sim1+/- mice, showed a 74% reduction of PVN neurons projecting to the DVC. However, the molecular composition of the cells affected by a decrease of Sim1 remains unknown. These results indicate that Sim1 haploinsufficiency: i) specifically interferes with the development of OT- and VP-producing cells; and ii) abolishes the development of a subset of parvocellular neurons that project to the DVC. These observations therefore raise the possibility that developmental defects contribute to the obesity phenotype of Sim1+/- mice. Second, we observed that pair-fed Sim1+/- mice do not gain more weight than littermate controls from 4 to 16 weeks of age. Moreover, qualitative and quantitative analyses showed significant increases of lean and fat mass, with hyperplasia of white adipose tissue and hypertrophy of brown adipose tissue, in Sim1+/- mice, but not in pair-fed animals. Additionally, at 16 weeks of age, insulin levels as well as liver and adipose tissue triglyceride content were not significantly different between Sim1+/+ and Sim1+/- pair-fed, but were significantly increased in Sim1+/- fed ad libitum. These results suggest that hyperphagia is the main if not the sole contributor to the obesity of Sim1+/- mice. They indicate that: i) Sim1 haploinsufficiency affects mainly food intake with no effect on energy expenditure; ii) food intake and energy expenditure are regulated by divergent pathways within the PVN; and iii) Sim1 haploinsufficiency specifically affects the feeding pathway without interfering with the thermogenesis pathway. Third, we found that, in both mice genotype, injection of MTII, leptin or CCK induces a significant decrease in cumulative food intake. In fact, MTII i.p. injection decreases cumulative food intake of Sim1+/- and Sim1+/+ mice by 37% and 51% respectively, when compared to saline injection. Leptin i.c.v. injection reduces cumulative food intake by 47% and 32% in Sim1+/- and Sim1+/+ mice, respectively. Finally, CCK i.p. injection decreases food intake of Sim1+/- and Sim1+/+ mice by 52% and 36%, respectively. All in all, the results of these latter studies suggest that Sim1 haploinsufficiency diminishes the activity of neuronal pathways regulating energy homeostasis, in particular of pathways controlling food intake. In conclusion, our work has shown that Sim1 haploinsufficiency affects several developmental processes of the PVN. These developmental defects may cause the dysfunction of physiological processes regulated by the PVN, including the control of food intake, and thus contribute to the hyperphagic obesity phenotype. Sim1 heterozygous mice represent an interesting animal model of obesity in which hyperphagia is the main, if not the sole mechanism of their obesity. These mice could therefore represent a unique opportunity to investigate cellular and molecular mechanisms in control of food intake.

Although research has linked the central nervous system with changes in immunoresponsivity, research on the possible role of the central nervous system in altering reticuloendothelial activity is lacking. This study investigated the possible relationship between hypothalamic structures and changes in responsivity of the reticuloendothelial system. Eight male albino rats received bilateral electrode implants in the ventromedial area of the hypothalamus and, following brain stimulation, reticuloendothelial activity was assessed 3, 6, 12, 24, and 96 hours after stimulation. Brain stimulation decreased phagocytic activity of the reticuloendothelial system. These findings may increase our understanding of a possible neural mechanism underlying relationships between stress and resistance to disease states.

Les neurones exprimant l'hormone de mélano-concentration (MCH) sont observés dans l'hypothalamus postérieur de tous les vertébrés, de la lamproie à l'Homme. Ces neurones sont impliqués dans diverses fonctions comme le cycle veille/sommeil ou la prise alimentaire. Ils forment une population non homogène et au moins deux sous-populations sont reconnues, chez le rat. La première sous-population est composée de neurones nés au 11ème jour de vie embryonnaire (E11) qui projettent massivement sur les régions les plus postérieures du système nerveux central. La seconde est générée à E12/E13 et les neurones la caractérisant projettent sur les régions les plus antérieures du cerveau et expriment le peptide CART (cocaine and amphetamine regulated transcript) et le récepteur NK3 (neurokinine). L'objectif de notre travail était de comprendre l'origine de ces deux sous-populations. Pour cela, nous avons utilisé des approches histologiques, moléculaires et in vitro. Les neurones à MCH sont parmi les premiers neurones à naître et à différencier leur phénotype chimique le long d'une région longitudinale définie par une prolifération intense, appelée " cell cords " par Keyser en 1972. Cette bande longitudinale est caractérisée par l'expression de gènes comme Sonic Hedgehog (Shh), Nkx2.1, Nkx2.2 et a été récemment renommée " diagonale intrahypothalamica " ou ID. La différenciation des neurones à MCH dépend de l'expression du facteur morphogène Shh et ces neurones expriment Nkx2.1 et Nkx2.2, facteurs de transcription régulés positivement par Shh. Les neurones de la première sous-population envoient des projections le long du premier tractus longitudinal à se mettre en place, le tractus postopticus (tpoc). Ceux issus de la deuxième sous-population se différencient concomitamment au développement des régions télencéphaliques et leurs projections changent de direction pour innerver les régions antérieures du cerveau sous la dépendance de protéines de guidage axonal, Nétrine1 et Slit2. Nétrine1 permet d'attirer les axones MCH exprimant le récepteur DCC précocement vers la moelle épinière et plus tardivement vers le télencéphale alors que Slit2 contraint les axones MCH exprimant Robo2 à sortir de l'hypothalamus. L'étude du modèle " MCH " permet de mettre en lumière un changement d'organisation précocement au cours du développement dans l'axe longitudinal du prosencéphale. La bande longitudinale d'expression des facteurs de transcription Shh, Nkx2.2 peut être perçue comme une extension rostrale de la colonne neurogénique médiane déjà décrite chez des espèces d'invertébrés possédant une symétrie bilatérale. Les neurones générés le long de cette colonne le sont très tôt au cours du développement. / Neurons expressing melanin-concentrating hormone (MCH) are observed in the vertebrate posterior hypothalamus, from lampreys to humans. These neurons are involved in various functions such as sleep/wake cycle or food intake. They form a non-homogeneous population and at least two sub-populations are indentified in the rat. The first sub-population is composed of neurons born on the 11th embryonic day (E11) that project heavily on posterior regions of the central nervous system. The second is characterized by neurons born at E12/E13, projecting in anterior regions of the brain and expressing the peptide CART (cocaine and amphetamine Regulated Transcript) and the NK 3 receptor (neurokinin). The aim of this study was to understand the origin of these two sub-populations. For this, we used histological, molecular and in vitro approaches. MCH neurons are among the first neurons to be born and to differentiate their chemical phenotype along a longitudinal region defined by intense proliferation and called " cell cord " by Keyser in 1972. This longitudinal band is characterized by the expression of genes such as Sonic Hedgehog (Shh), Nkx2.1, Nkx2.2 and was recently named " diagonal intrahypothalamica " or ID. Differenciation of MCH neurons depends on expression of the morphogenetic factor Shh and these neurons express Nkx2.1 and Nkx2.2, transcription factors upregulated by Shh. The neurons of the first sub-population send projections along the tractus postopticus (tpoc), which is the first longitudinal tract to develop. Neurons of the second sub-population differentiate concomitantly to the development of the basal forebrain and their projections innervate anterior brain regions. Our results obtained in vitro showed that Netrin1 attracts MCH axons and that this reponse is mediated by DCC. Slit2 repulses MCH axons and this reponse is mediated by the Robo2 receptor. Overall, our study of the development of the MCH system shed light on an organizational change in the longitudinal axis of the forebrain during early development : a primary longitudinal organization characterized by the longitudinal expression of Shh and Nkx2.2 and the path of the tractus postopticus in the diencephalon and mesencephalon. MCH neurons of the first sub-population develop during this stage. Then, as the basal telencephalon extends and expresses Netrin1, the medial forebrain bundle differentiates, inducing a change in the main axis of the forebrain ; meanwhile MCH neurons of the second sub-population appear. MCH sub-populations reflect distinct developmental stages of the forebrain.

As projeções OTérgicas do PVN que se projetam para o tronco cerebral são responsáveis por mediar os ajustes da FC e esses efeitos benéficos induzidos pelo TF são abolidos pela desnervação sinoaórtica (DAS). Iremos determinar o efeito do treinamento e da DAS sobre os neurônios OTérgicos do PVN em SHR e WKY. Os ratos foram submetidos DSA ou SHAM e treinados ou mantidos sedentários por três meses. Realizou-se medidas hemodinâmicas basais seguidas de retirada dos cérebros. Nos ratos SHAM o TF determinou um aumento na capacidade física e no ganho do controle reflexo da FC. O TF reduziu a FC de repouso em ambos os grupos, com uma queda na pressão arterial nos SHR. Houve aumento da expressão de mRNA para OT no PVN e na densidade de OT nos neurônios OTérgicos do PVN. A DSA aboliu a expressão do mRNA de OT no PVN e reduziu drasticamente a densidade de OT no PVN de WKY e SHR. A DSA revela o papel fundamental dos barorreceptores em mediar a plasticidade/atividade dos neurônios OTérgicos do PVN como os efeitos benéficos do treinamento sobre o controle cardiovascular. / The OTergic projections from PVN to the dorsal brainstem mediate training-induced HR adjustments and that beneficial effects of training are blocked by sinoaortic denervation (SAD). We sought now to determine the combined effect of training and SAD on PVN OTergic neurons in SHR and WKY. Rats underwent SAD or SHAM surgery and were trained or kept sedentary for 3 months. After hemodynamic measurements at rest, the brains were removed. In SHAM rats, training improved treadmill performance and increased the gain of baroreflex control of HR. Training reduced resting HR in both groups, with a fall in blood pressure only in SHR rats. These changes were accompanied by marked increases in PVN OT mRNA expression and peptide density in PVN OTergic neurons. SAD abolished PVN OT mRNA expression and markedly reduced PVN OT density in WKY and SHR. Training had no effect on HR, PVN OT mRNA, or OT content following SAD. SAD uncovers the pivotal role of barorreceptor in driving both the plasticity and activity of PVN OTergic neurons and the beneficial effects of training on cardiovascular control.

Relações entre machos de roedores muitas vezes se dão com a manifestação de comportamentos agressivos, em um embate em que se define um perdedor e um ganhador. O macho perdedor, de acordo com experimentos realizados no laboratório, apresenta comportamentos de defesa (avaliação de risco) quando exposto ao contexto da derrota social. Na expressão da defesa condicionada, estruturas do hipotálamo lateral devem ser importantes, que são também mobilizadas durante o confronto. No hipotálamo lateral destacamos a a parte justadorsomedial do hipotálamo lateral (LHAjd) que tem conexões com o sistema septo-hipocampal e projeta-se liga ao prémamilar dorsal (PMD), crítico para a expressão de comportamentos de defesa. Por outro lado, o PMD, que é uma estrutura altamente mobilizada durante o confronto social, tem conexões com o núcleo anteromedial do tálamo (AMv), estrutura já conhecida pela sua importância na aquisição da memória contextual e espacial. Assim, no presente trabalho, investigamos o papel do LHAjd na expressão e do AMv na aquisição da defesa condicionada na derrota social. Nos animais com lesão do LHAjd, observamos diminuição nos comportamentos de avaliação de risco durante exposição ao contexto. Nos animais com lesão do AMv o mesmo efeito. Dado os efeitos das lesões no AMv, elaboramos um paradigma para estudo em camundongos, a fim de se realizar inativações pontuais com farmacogenética nos neurônios glutamatérgicos em animais transgênicos durante a derrota social. Foi observado o mesmo padrão em camundongos transgênicos vGlut2-cre inativados com farmacogenética, não havendo influência nos comportamentos durante a derrota social. Inativações antes do contexto não causaram efeito na defesa condicionada. As inativações durante a derrota, no entanto, não tiveram efeito quando o residente agressivo está na exposição ao contexto. Os dados sugerem que o LHAjd tem papel na expressão da defesa condicionada, enquanto que o AMv tem papel na aquisição da defesa condicionada ao contexto, mas não no reconhecimento do residente agressivo. / Male rodents may interact aggressively, and from the agonistic encounter, it results a winner and a defeated animal. Accordingingly, the defeated male shows defensive behaviors (risk assessment) to the social defeat-related context. Contextual responses are known to rely on hippocampal processing, and one of the main targets of the hippocampal system is the justodorsomedial part of lateral hypothalamus (LHAjd), which projects to dorsal premamillary nucleus (PMD), known to be involved in the expression of social defensive behaviors. Notably, PMD, a hypothalamic site highly responsive to the social defeat, in turn, projects to the ventral part of thalamic anteromedial nucleus (AMv), previously shown to be involved in the acquistion of spatial and contextual memory to predatory threats. Thus, in present study, we investigated the role of LHAjd in expression and of AMv in acquisition of social defeat conditioned defensive behaviors. In LHAjd lesioned animals, we observed a decrease in risk assessment behaviors during exposute to the social defeat associated context , but not during the social defeat itself, suggesting a role in the expression of contextual but not in the innate social defeat. In AMv lesioned animals, we observed that the animals lost contextual defensive response, suggesting a role in the acquisition and/or expression of contextual responses. Next, using pharmacogetic inhibition, we investigated in vGlut2-cre transgenic mice the role of the AMV in the acquisition and expression of contextual defensive behavior. We have found that AMV inactivation prior to the social defeaf, but not prior to the exposure to the social defeat related context, was able to decrease contextual responses in animals tested withot the presence of the male aggressor, but not in the situation where the male aggressor was present. Overall, our results suggest that the LHAjd has a role in the expression of conditioned defense, and that the AMV is involved in the acquisision of contextual fear responses, but not in social recognition of aggressive male.

Os piretróides sintéticos, em especial os do tipo II, como a cialotrina, são extensivamente utilizados para o controle de uma ampla variedade de ectoparasitas que acometem os animais de produção. Entretanto, no Brasil e em outros países, sua utilização vai além da saúde animal, sendo utilizados também em saúde pública, no controle de diversos vetores, como é o caso do vetor da dengue, dentre outros. Visto que a cialotrina modifica a atividade de macrófagos peritoneais, o objetivo deste trabalho foi investigar os prováveis mecanismos através dos quais este piretróide modifica a atividade destas células. Os presentes resultados, analisados em seu conjunto, mostram de maneira inequívoca que a cialotrina tem um efeito direto e/ou indireto sobre a atividade de macrófagos peritoneais. Especificamente, observou-se neste trabalho que o praguicida causou em ratos: 1 ? marcação fos positiva em neurônios do núcleo paraventricular do hipotálamo (NPH), após a dose de 3,0 mg/kg/dia; 2 - diminuição do percentual e intensidade de fagocitose de macrófagos peritoneais ativados e avaliados por citometria de fluxo; 3 - diminuição dose-dependente da produção de nitrito (NO2); 4 ? diminuição do percentual e intensidade de fagocitose de macrófagos peritoneais ativados, em ratos adrenalectomizados e/ou tratados com metirapona (inibidor da síntese de corticosterona) e RU 486 (antagonista de receptores glicocorticóides) com a finalidade de modular os níveis de glicocorticóides, e tratados com 3,0 mg/kg/dia de cialotrina; 5 ? aumento dos níveis de noradrenalina hipotalâmica em animais tratados com a dose de 3,0mg/kg/dia de cialotrina; 6 - diminuição do percentual e intensidade de fagocitose, bem como diminuição da produção de nitrito de macrófagos peritoneais ativados, em ratos simpatectomizados químicamente com 6-OHDA; 7 - diminuição dose dependente do percentual e intensidade de fagocitose, bem como da produção de nitrito de macrófagos peritoneais ativados e tratados in vitro com 10 e 100 nM de cialotrina. No entanto, não observamos: 1 ? alterações na produção de nitrito realizada por macrófagos peritoneais ativados, em ratos adrenalectomizados e/ou tratados com metirapona e RU 486; 2 - alterações na viabilidade celular induzida pelo tratamento in vitro com a cialotrina na concentração de 10 e 100 nM e 3 ? alterações nos efeitos da cialotrina sobre a atividade de macrófagos tratados in vitro com os ligantes de receptores benzodiazepínicos periféricos. Em conjunto, os presentes dados mostram que a cialotrina interfere com a atividade de macrófagos por atuar indiretamente, através da ativação do eixo Hipotálamo-Hipófise-Adrenal (HHA), e/ou diretamente sobre os mesmos modulando sua atividade. É muito provável que o efeito resultante do tratamento in vivo com este praguicida esteja ligado à somatória destas ações / Synthetic pyrethroids, particularly those of type II, such as cyhalothrin, are extensively used in agriculture for the control of a broad range of ectoparasites in farm animals. However, in Brazil and some other countries, these pyrethroids have also been used in public health, for the control of insects that are known to be vectors of diseases such as dengue. Since it has been suggested that cyhalothrin alters activity of peritoneal macrophages, the objective of our study was to investigate the putative mechanisms for the changes induced by pyrethroid in these cells. The results presented here show, in an unequivocal manner, that cyhalothrin has a direct or indirect (or both) effect on the activity of peritoneal macrophages. We specifically observed in this work that this pesticide induced in rats: 1- Fos-positive immunostaining in neurons of the paraventricular nucleus of the hypothalamus (NPH), after 3.0 mg/kg/day; 2 ? a reduction in the percentage and intensity of phagocytosis by activated peritoneal macrophages, evaluated by flow cytometry; 3 ? a dose-dependent reduction in nitrite production (NO2); 4 ? a reduction in the percentage and intensity of phagocytosis by activated peritoneal macrophage from adrenalectomized rats treated or not with metirapone (inhibitor of corticosterone synthesis) or RU 486 (antagonist of glicocorticoids receptors) with the propose of modulating the levels of glicocorticoids, and treated with 3.0 mg/kg/day of cyhalothrin; 5 ? an increase in the hypothalamic levels of noradrenaline in rats treated with 3.0 mg/kg/day of cyhalothrin; 6 ? a reduction in the percentage and intensity of phagocytosis and also a decrease in the production of nitrite by activated peritoneal macrophages, after chemical sympatectomy with 6-OHDA; 7 ? a dose-dependent reduction of the percentage and intensity of phagocytosis, and also a decrement in nitrite production by activated peritoneal macrophages treated in vitro with 10 and 100 nM of cyhalothrin. However, we found no differences on: 1 ? nitrite production by activated peritoneal macrophages after adrenalectomy, treated or not with metirapone or RU 486; 2 ?cell viability of peritoneal macrophages treated in vitro with 10 and 100 nM of cyhalothrin, and 3 ? the effects of cyhalothrin on macrophage activity after in vitro treatment with peripheral benzodiazepine receptor ligands. Altogether, the present results show that cyhalothrin interferes with the activity of peritoneal macrophages by acting indirectly, via activation of the hypothalamus-pituitary-adrenal axis, or directly on these cells, altering their activity. As a matter of fact, it is quite possible that the results of in vivo cyhalothrin treatment on macrophage activity would be related to the combined effect of these direct and indirect influences

Introdução: A urocortina 3 (UCN 3) é um neuropeptídeo pertencente a família CRF, com seletividade de ligação a receptor CRF2. Em roedores as células UCN 3 se localizam principalmente em hipotálamo e amígdala, mas o mapeamento não foi realizado em modelo de primata não-humano. Objetivo: realizar o mapeamento da distribuição da UCN 3 no sistema nervoso central na espécie Cebus apella. Material e métodos: cortes de encéfalo de animais machos foram submetidos aos métodos de imuno-histoquímica e hibridização in situ para UCN 3. Séries adjacentes foram coradas pelo método de Nissl e hematoxilina-eosina. Resultados: Células UCN 3 se localizam principalmente em regiões hipotalâmicas, amigdalóides e límbicas. Há colocalização de UCN 3/CRF no núcleo paraventricular do hipotálamo e UCN 3/insulina em células <font face=\"Symbol\">b do pâncreas. Conclusão: a distribuição de UCN 3 em primata não-humano é semelhante à de roedores. / Introduction: Urocortin 3 (UCN 3) is a neuropeptide with 38-aa and member of the CRF peptide family, it is a selective agonist for the CRF2 receptor. UCN 3 cells in rodents showed containing- neurons found mainly in hypothalamic and amygdaloid regions. However, such mapping was not done in a non-human primate model. Objective: study the UCN 3 distribution in the brain of a monkey. Material and methods: frontal sections (40<font face=\"Symbol\">mm) were subjected to immunohistochemistry technique and in situ hybridization, Nissl and Hematoxylin-eosin staining. Results: UCN 3 cells were found mainly in the amygdaloid, limbic and hypothalamic regions. Double-labeled cells (CRF/UCN 3) were found in the PaMD and, in <font face=\"Symbol\">b cells (UCN 3/insulin) of pancreas. Conclusion: the distribution of UCN 3 in non-human primate is similar to the rodents distribution.

Atualmente, é crescente o interesse em estudar o potencial do Sistema Nervoso Central (SNC) como alvo de medicamentos antidiabéticos, uma vez que ele possui receptores de insulina e desempenha papel crítico na regulação da homeostase glicêmica. Nesse sentido, o Cycloset® (mesilato de bromocriptina de liberação rápida), um medicamento de ação central aprovado nos Estados Unidos para o tratamento do DMT2, atende a essa tendência atual. Trabalhos prévios mostram efeitos benéficos da bromocriptina (Bromo) sobre a hiperglicemia e hiperlipidemia em modelos de animais obesos tratados com essa droga. Por ser um agonista dopaminérgico, um dos possíveis mecanismos de ação dessa droga pode ser bloqueando a liberação e produção de prolactina (Prl). Níveis elevados de prolactina na circulação sanguínea, observados tanto em indivíduos com prolactinomas como em pessoas tratadas com medicamentos que causam hiperprolactinemia, geram anormalidades no metabolismo de carboidratos e lipídeos, o que pode levar a um quadro de síndrome metabólica. Na presente tese, testamos a hipótese de que ao menos parte dos efeitos antidiabéticos da Bromo seja mediada pela inibição da secreção de prolactina. Avaliamos os efeitos do tratamento com Bromo em camundongos machos e fêmeas geneticamente obesos e resistentes à insulina (ob/ob), bem como testamos se os efeitos benéficos do medicamento seriam revertidos com a reposição de Prl. Machos tratados com Bromo apresentaram maior sensibilidade à insulina, enquanto que a reposição de Prl manteve os animais menos sensíveis, tais como os animais do grupo controle. As fêmeas tratadas com Bromo apresentaram tendência à melhora de sensibilidade à insulina, bem como foram mais tolerantes à glicose, sendo que a reposição de Prl em animais tratados com Bromo também reverteu o efeito benéfico do medicamento. Dessa forma, demonstramos que ao menos parte dos efeitos antidiabéticos da Bromo é mediada pela inibição da secreção basal de Prl. Em um segundo conjunto de experimentos, testamos se a administração de antagonistas de prolactina (G129R-hPrlR) em machos ob/ob, por vias centrais ou periféricas, produziria efeito antidiabético. Observamos que tanto o tratamento periférico como o central diminui a curva glicêmica dos animais em testes de tolerância à glicose e melhoram a sensibilidade à insulina, embora ainda não tenhamos obtido valores significativos devido a nossa amostragem. Por fim, investigamos se a ação da Prl sobre o metabolismo ocorre por meio da interação com o receptor de estrógeno alfa (ER&#945;). Verificamos que receptores de prolactina e de ER&#945; são expressos em áreas comuns no SNC e que variações nos níveis circulantes de estrógeno causam mudanças na sensibilidade à prolactina. Portanto, no presente trabalho, identificamos o possível mecanismo pelo qual a Bromocriptina promove melhorias no controle glicêmico e, de forma inédita, produzimos evidências que o uso de antagonistas de prolactina pode ter potencial no tratamento do DMT2. / Type 2 Diabetes mellitus (T2DM) is a syndrome characterized by dysfunctions in the metabolism of glucose, amino acids and free fat acids. Although most of the drugs currently used to treat T2DM targets peripheral organs, a growing interest in studying the Central Nervous System (CNS) as a potential target of antidiabetic drugs is appearing. The CNS possesses insulin receptors and plays a critical role in regulating glucose homeostasis. In this sense, Cycloset® (quick release bromocriptine mesylate) a drug that acts on CNS, was recently approved in United States to treat T2DM. Previous studies have shown beneficial effects of bromocriptine (Bromo) on hyperglycemia and hyperlipidemia in obese animal models. As a dopaminergic agonist, a possible mechanism of action of this drug could be caused by a decreased prolactin (Prl) production and release. High serum prolactin levels, as observed in patients bearing prolactinomas or individuals using drugs that induce hyperprolactinemia, generate abnormalities in carbohydrate and lipid metabolism, which can lead to metabolic syndrome. In the current thesis, we tested the hypothesis that part of bromocriptine antidiabetic effects is due to an inhibition of prolactin secretion. We evaluated Bromo effects in genetically obese and insulin resistant male and female mouse (ob/ob), as well as we tested whether replacing Prl could reverse the beneficial effects of Bromo. Males treated with Bromo showed lower insulin resistence, whereas Prl replacement decreased insulin sensitivity. Females treated with Bromo showed tendency towards an improvement in their insulin sensitivity and glucose tolerance. Prl replacement also reversed the beneficial effects of Bromo in this group. Thus, we demonstrated that at least part of the antidiabetic effects of Bromo is due to inhibition of Prl secretion. In another set of experiments, we tested whether central or peripheral treatment with prolactin antagonists (G129R-hPrlR) causes antidiabetic effects in ob/ob male mice. Both peripheral and central treatment decreased the glycemic curve during glucose and insulin tolerance tests, although we still did not obtain statistically significant values with our sample size. Lastly, we investigated whether metabolic Prl action occurs due to a putative interaction with estrogen receptor alpha (ER&#945;). We found a wide co-expression between Prl receptor and ER&#945; in the CNS. Additionally, changes in estrogen levels decrease prolactin sensitivity. Therefore, in the present study we identified the possible mechanism by which bromocriptine promotes improvements in glycemic control, and for the first time, we obtained evidence that the use of prolactin antagonists can have a potential effect in the treatment of T2DM.